• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.24% Nasdaq Down0.34%

    ProPhase Labs, Inc. (PRPH)

    -NasdaqGM
    1.38 Up 0.01(0.62%) 12:06PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    ProPhase Labs, Inc.
    621 North Shady Retreat Road
    Doylestown, PA 18901
    United States - Map
    Phone: 215-345-0919
    Website: http://www.prophaselabs.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Related Products
    Full Time Employees:54

    Business Summary 

    ProPhase Labs, Inc. manufactures, markets, and distributes a range of homeopathic and health products in the United States. The company also researches and develops over-the-counter (OTC) drugs, natural base health products with supplements, personal care, and cosmeceutical products. It offers Cold-EEZE, a zinc gluconate lozenge used to reduce the duration of the common cold; and non-lozenge forms of its proprietary zinc gluconate formulation, including Cold-EEZE cold remedy QuickMelts and Cold-EEZE cold remedy oral spray. The company’s Cold-EEZE cold remedy QuickMelts product line consist of Cold-EEZE daytime/nighttime QuickMelts, Cold-EEZE Plus Immune Support + Energy QuickMelts, and Cold-EEZE plus multi-symptom QuickMelts. ProPhase Labs, Inc. also provides organic cough drops and a Vitamin C supplement under the Organix trademark; and contract manufacturing services of cough drop, dietary supplements, and other OTC cold remedy products for third parties, as well as produces private label lozenge products for retail customers. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation and changed its name to ProPhase Labs, Inc. The company was founded in 1989 and is headquartered in Doylestown, Pennsylvania.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on ProPhase Labs, Inc.

    Key Executives 
     PayExercised
    Mr. Ted William Karkus , 56
    Chairman and Chief Exec. Officer
    751.00K0.00
    Mr. Robert V. Cuddihy Jr., 55
    Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer and Exec. VP
    479.00K0.00
    Mr. James T. McCubbin , 51
    Compliance Officer, Independent Director and Member of Audit Committee
    31.00KN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders